Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.61 |
| ▸ | MTOR | P42345 | 4/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067863 | 0.94 | PIK3CA (0.56) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL4947574 | 0.83 | KDM1A (0.48) | PIK3CAPIK3R1PIK3CDPIK3CBACHE | |
| SCHEMBL10187275 | 0.83 | KDM1A (0.48) | PIK3CAPIK3R1PIK3CDPIK3CBACHE | |
| SCHEMBL9900073 | 0.81 | KDM1A (0.47) | PIK3CAPIK3R1PIK3CDPIK3CBACHE | |
| SCHEMBL5457199 | 0.80 | PIK3CA (0.55) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL5525967 | 0.80 | PIK3CA (0.58) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL568875 | 0.79 | PIK3CA (0.55) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL23593463 | 0.79 | PTPN11 (0.48) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL23593434 | 0.79 | OGA (0.42) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL3896595 | 0.79 | PIK3CA (0.54) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240374590-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | COILED THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | PIK3CA 2916/4885PIK3R1 1606/4885PIK3CD 2234/4885 |
| US-20240374590-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NTPCR, PTPRC, NFATC1 | PIK3CA 344/4885PIK3R1 924/4885PIK3CD 443/4885 |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | PIK3CA 42/4885PIK3R1 171/4885PIK3CD 86/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | PIK3CA 42/4885PIK3R1 171/4885PIK3CD 86/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | PIK3CA 2916/4885PIK3R1 1606/4885PIK3CD 2234/4885 |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | PIK3CA 42/4885PIK3R1 171/4885PIK3CD 86/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | PIK3CA 42/4885PIK3R1 171/4885PIK3CD 86/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | PIK3CA 2916/4885PIK3R1 1606/4885PIK3CD 2234/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | PIK3CA 41/4885PIK3R1 171/4885PIK3CD 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.